Letrozole cas:112809-51-5 CAS NO.112809-51-5

FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
Min.Order: 1 Gram
Payment Terms: ,Other
Available Specifications:
top(1-10)Gram1/Gram1USD

Product Details

Keywords

Femara
Letrozcle
stimulant steroid

Quick Details

ProName: Letrozole cas:112809-51-5
CasNo: 112809-51-5
Molecular Formula: C17H11N5
Appearance: White to off-white crystalline powder
Application: For research purposes only
DeliveryTime: One day
PackAge: Discreet packing ways as your requirem...
Port: Guangzhou;Shanghai;Shenzhen;HK
ProductionCapacity: 100 Kilogram/Day
Purity: 99.8%
Storage: Keep in a cool and dry place
Transportation: shipping by EMS,DHL,TNT,FEDEX,UPS or a...
LimitNum: 1 Gram
Moisture Content: 0%
Impurity: 0%

Superiority

Our advantage:

1.High quality with competitive price:

1)Standard: enterprise standard

2)All purity¡ý99%

3)We are manufacturer and can provide high quality products with factory price.

2.Fast and safe delivery

1)Parcel can be sent out in 24 hours after payment. tracking number available

2)Secure and discreet shipment. various transportation methods for your choice.

3)Customs pass rate ¡ý99%

4)We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.

3.We have clients throughout the world.

1)Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.

2)Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.

3)High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.

Everybody is talking the similar words, what i want to say is: just give me a chance, just have a try on me, maybe you will get a surprise from me!

Details

INDICATIONS

Adjuvant Treatment Of Early Breast Cancer

Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Extended Adjuvant Treatment Of Early Breast Cancer

Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with Femara for a median of 60 months

First And Second-Line Treatment Of Advanced Breast Cancer

Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy

DOSAGE AND ADMINISTRATION

Recommended Dose

The recommended dose of Femara is one 2.5 mg tablet administered once a day, without regard to meals.

Use In Adjuvant Treatment Of Early Breast Cancer

In the adjuvant setting, the optimal duration of treatment with letrozole is unknown. In both the adjuvant study and the post approval adjuvant study, median treatment duration was 5 years. Treatment should be discontinued at relapse .

Use In Extended Adjuvant Treatment Of Early Breast Cancer

In the extended adjuvant setting, the optimal treatment duration with Femara is not known. The planned duration of treatment in the study was 5 years. In the final updated analysis, conducted at a median follow-up of 62 months, the median treatment duration for Femara was 60 months. Seventy-one (71%) percent of patients were treated for at least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. The treatment should be discontinued at tumor relapse .

Use In First And Second-Line Treatment Of Advanced Breast Cancer

In patients with advanced disease, treatment with Femara should continue until tumor progression is evident.

Use In Hepatic Impairment

No dosage adjustment is recommended for patients with mild to moderate hepatic impairment, although Femara blood concentrations were modestly increased in subjects with moderate hepatic impairment due to cirrhosis. The dose of Femara in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see WARNINGS AND PRECAUTIONS]. The recommended dose of Femara for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on Femara exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined.

Use In Renal Impairment

No dosage adjustment is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/min

FAQ

1. Can I get a free sample

Yes, but you have to pay the courier fee.

2. How to pay

We accept payments in the form of , MoneyGram, Bitcoin, etc.

3. What should I do if we don’t ship after payment

We are a formal company certified by LOOKCHEM Integrity, you can provide proof of payment to LOOKCHEM complaints.

4. How long after the payment can be shipped

We have stocked products that are shipped within 24 hours. If you need to customize the product, we will negotiate the delivery cycle.

5. How is the safety of transportation

We will choose the safest delivery method to ensure customs clearance and safety during transportation.

6. What kind of company is THETA BIO

In 2009, Dr Zhang Lin from Johns Hopkins University founded the theta Biological Laboratory. He is committed to the study of protein assimilation preparations.

In 2013,Dr Zhang Lin returned to China to work in MSD China, and continued to work on biopharmaceutical research and development.

In 2018,Dr Zhang Lin founded shaoyang Theta Biological Thechnology Co.,Ltd.

Business Scope:

Pharmaceutical intermediate

Biotechology development

Fine organic chemistry

Biopharmaceutical

History of the company

In 2009,Dr Zhang Lin from Johns Hopkins University founded the theta Biological Laboratory.He is committed to the study of protein assimilation preparations.